Tyra Biosciences Q3 net loss $24M; cash $360M; positive interim TYRA-300 mUC data

Tyra Biosciences, Inc.

2024-Q3 EPS reported -$1.08

Net loss $24.0M in Q3 2024 vs $21.2M in Q3 2023; R&D expense $22.7M, up from $19.3M.
Cash, equivalents, and marketable securities $360.1M; runway through at least 2026.
TYRA-300 interim data: at ≥90 mg QD, 6/11 (54.5%) mUC patients with FGFR3+ had confirmed PR; 100% disease control.
FDA cleared IND for Phase 2 achondroplasia study (BEACH301); first child dosing expected Q1 2025.
Appointed Doug Warner as Chief Medical Officer, effective September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.